seed fundingOxford-based cancer vaccine company Infinitopes closes $35 million seed roundInfinitopes, a U.K. cancer vaccine biotech spun out of Cancer Research U.K. and the University of Oxford, has expanded its seed round to $35.1 million after a second close that added about $15.4 million … more ➔
TrendsA changing playing field: Observations of the 2026 JP Morgan Healthcare Conference from a European perspectiveThe Westin St. Francis lobby buzzed with its familiar January energy, a peculiar blend of jet lag, ambition, and the faint desperation of biotech CEOs clutching coffee cups like lifelines. This year’s … more ➔
QiagenQiagenTakeover rumours at Qiagen fuel share price surgeWith the departure of the current CEO of diagnostics company Qiagen NV (Venlo, Netherlands/Hilden, Germany) and before a new chief executive has been identified and presented, there appears to be activity … more ➔
Series AFrench biotech ErVimmune raises €17M to advance off-the-shelf cancer vaccine targeting HERVsThe French preclinical-stage biotech ErVimmune closed a €17 million series A round to bring its lead candidate cancer vaccine into the clinic. more ➔
AcquisitionGSK strengthens food allergy ambitions with $2.2bn RAPT Therapeutics acquisitionGSK has agreed to acquire California-based RAPT Therapeutics in a deal valued at $2.2 billion (€ 1.88 billion), expanding its respiratory, immunology and inflammation portfolio with a late-stage food … more ➔
Freepik.comFinancingHeidelberg-based Exciva secures €51M to tackle agitation in Alzheimer’s careAlzheimer’s disease means memory loss for those affected. Beyond this, however, it is above all relatives and care staff who are impacted when the loss of cognitive abilities is accompanied by symptoms … more ➔
IPOAgomAb files for U.S. IPO as fibrosis-focused pipeline moves deeper into the clinicAgomAb Therapeutics has filed for an initial public offering (IPO) in the U.S., looking to tap public markets to fund the next stage of development for its pipeline in fibrotic and inflammatory diseases. … more ➔
Clinical trialGenmab and AbbVie’s epcoritamab fails in phase 3 lymphoma studyLast week, Genmab and AbbVie hit a setback with epcoritamab, after the bispecific T-cell-engaging antibody failed to deliver a survival benefit in a phase 3 study in relapsed or refractory diffuse large … more ➔
Licence agreementGenethon licenses core AB-1009 technology to AskBio after IND clearanceFrench gene therapy research institute Genethon announced it has signed an exclusive global license with AskBio that allows the company to use Genethon-patented technology incorporated in AB-1009, an … more ➔
RegulatoryEMA and FDA join forces: Aligned principles on AI use in drug developmentThe European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have together compiled ten principles for good artificial intelligence (AI) practice in drug development. more ➔
Qiagen
Freepik.com
